<DOC>
	<DOCNO>NCT01323634</DOCNO>
	<brief_summary>The purpose study evaluate 24-hour spirometry effect ( FEV1 ) FF/VI 100/25mcg daily compare Fluticasone Propionate/Salmeterol 250/50mcg twice daily 12-week treatment period subject COPD .</brief_summary>
	<brief_title>Study Evaluate 24-Hour Pulmonary Function Profile Fluticasone Furoate ( FF ) /GW642444 ( Vilanterol ) ( VI ) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily Subjects With Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description>This randomize , double-blind , double-dummy , multi-centre parallel group study . Subjects meet eligibility criterion Screening meet randomization criterion end 2-week Run-In period enter 12-week treatment period . There 7-day Follow-up period treatment period .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Respiratory Aspiration</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Signed date write informed consent Male females ≥ 40 year age Established clinical history COPD ATS/ERS definition Females eligible enter participate nonchildbearing potential , child bear potential , negative serum pregnancy test screening , agree one acceptable contraceptive method list protocol , use consistently correctly Former current smoker &gt; 10 pack year Postalbuterol spirometry criterion : FEV1/FVC ratio ≤ 0.70 FEV1 ≤ 70 % predict normal ( NHANES III ) Current diagnosis asthma Subjects respiratory disorder include active tuberculosis , α1antitrypsin deficiency , lung cancer , bronchiectasis , sarcoidosis , lung fibrosis , pulmonary hypertension , interstitial lung disease active pulmonary disease Lung volume reduction surgery within previous 12 month Clinically significant abnormality due COPD chest xray Hospitalized poorly control COPD within 12 week Screening Poorly control COPD 6 week prior Screening , define acute worsen COPD manage subject corticosteroid antibiotic require treatment prescribed physician Lower respiratory infection require antibiotic 6 week prior Screening Uncontrolled clinically significant ( opinion PI ) cardiovascular , hypertension , neurological , psychiatric , renal , hepatic , immunological , endocrine , peptic ulcer disease , hematological abnormality Carcinoma complete remission least 5 year Subjects history hypersensitivity study medication ( e.g. , betaagonists , corticosteroid ) component inhalation powder ( e.g. , lactose , magnesium stearate ) Subjects history severe milk protein allergy , opinion study physician , contraindicate subject 's participation Known/suspected history alcohol drug abuse last 2 year Women pregnant lactate plan become pregnant Subjects medically unable withhold albuterol and/or ipratropium 4 hour prior spirometry test study visit Use certain medication bronchodilator corticosteroid protocolspecific time prior Visit 1 ( Investigator discuss specific medication ) Long Term Oxygen Therapy ( LTOT ) nocturnal oxygen therapy &gt; 12 hour day Participation acute phase pulmonary rehabilitation program within 4 week prior Screening study Noncompliance inability comply study procedure schedule visit Affiliation investigator site</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>